Disease modification in OA — will we ever get there?

No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Challenges for DMOAD trial design.


  1. 1.

    McAlindon, T. E. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 22, 363–388 (2014).

  2. 2.

    Kraus, V. B. et al. Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA’s accelerated approval regulations for disease modifying osteoarthritis drugs. Osteoarthritis Cartilage https://doi.org/10.1016/j.joca.2018.11.002 (2018).

  3. 3.

    National Joint Registry. Joint replacement statistics. njrcentre http://www.njrcentre.org.uk/njrcentre/Patients/Joint-replacement-statistics (2017).

  4. 4.

    Hunter, D. J. Pharmacologic therapy for osteoarthritis —the era of disease modification. Nat. Rev. Rheumatol. 7, 13–22 (2011).

  5. 5.

    Deveza, L. A. et al. Trajectories of femorotibial cartilage thickness among persons with or at risk of knee osteoarthritis: development of a prediction model to identify progressors. Osteoarthritis Cartilage 27, 257–265 (2019).

  6. 6.

    Neogi, T. et al. Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. BMJ 339, b2844 (2009).

  7. 7.

    Neogi, T. & Felson, D. T. Bone as an imaging biomarker and treatment target in OA. Nat. Rev. Rheumatol. 12, 503–504 (2016).

  8. 8.

    Gossec, L. et al. The role of pain and functional impairment in the decision to perform total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. Osteoarthritis Cartilage 19, 147–154 (2011).

  9. 9.

    Tubach, F. et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann. Rheum. Dis. 64, 34–37 (2005).

  10. 10.

    Ingelsrud, L. H. et al. Meaningful change scores in the knee injury and osteoarthritis outcome score in patients undergoing anterior cruciate ligament reconstruction. Am. J. Sports Med. 46, 1120–1128 (2018).

Download references

Author information

Correspondence to L. Stefan Lohmander.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading